Parag Milk Foods Ltd

- There is no explicit mention of any new fundraising plans through debt or equity in the provided transcript. - The company reports a debt level of around Rs. 260 crores as of December 2018, largely similar to previous quarters, with some long-term loans including a forex loan from IFC World Bank. - They incurred Rs. 60 crore CAPEX in the first 9 months, mainly including the Sonipat plant, with no substantial CAPEX planned in the near term. - Due to anticipated free cash flow generation in the next two years, the company is evaluating options including partial debt repayment. - The management is assessing how to deploy free cash flow, balancing infrastructure investment (mainly compliance and cold chain within existing plants) and debt reduction. - No definitive decision on raising fresh debt or equity has been shared as of February 2019.

- CAPEX in first 9 months of FY19 was about Rs. 59-60 crores, including investment in the Sonipat plant. - No substantial additional CAPEX is expected in the next 3 months of FY19; total FY19 CAPEX likely around 2.5% of revenue. - Future CAPEX mainly compliance-related within existing plants (e.g., quality, safety, and operational compliance) rather than new plant setups. - Investments have been made recently in cold chain infrastructure and transportation to support growth and improve working capital. - Free cash flow expected to increase over next 2 years due to limited CAPEX needs. - Company evaluating options to deploy free cash flow, including potential partial debt repayment and further investments in infrastructure to support long-term growth. - Sonipat plant procurement network being developed, but it is still early stage; target to scale procurement gradually over next 1-2 years. Overall, capital investments are focused on compliance upgrades, cold chain/transport enhancements, and capacity utilization within existing facilities rather than new large-scale CAPEX.

- Parag Milk Foods aims to grow health and nutrition segment sales to 6-7% of overall topline by FY21, up from 2.5-3% currently. - The company targets improving EBITDA margins to 11-12% in FY20 driven by better product mix and operational efficiencies. - Value-added products like paneer, cheese, and whey protein are expected to grow faster than average, contributing to margin expansion. - Distribution network expanded to around 3 lakh outlets, with continued focus on deepening reach, especially in northern and eastern regions. - The Avvatar brand, including whey protein variants, is expected to see significant sales growth going forward. - The company anticipates normal inflationary milk price increases (~5-7%), managing cost pass-through to protect margins. - CAPEX planned at around 2.5% of revenue aims to support growth without substantial new capacity additions.

- Parag Milk Foods expects EBITDA margins of 11% to 12% in FY20, driven mainly by improved product mix and operating efficiencies. - Operating cash flow for the first 9 months of the current year is about Rs.100 crores, with free cash flow generation expected to remain strong due to limited CAPEX needs over the next 2 years. - Health and nutrition segment gross margins are expected to exceed 40% once matured, potentially boosting overall margins. - Growth in value-added products like paneer, cheese, whey protein, and curd is higher than the company’s average, supporting better profitability. - Marketing and advertisement expenses are planned at around 2.5% - 3% of sales to support growth while maintaining margin expansion. - Normal milk price inflation of 5-7% is anticipated, with the company managing margin impacts through pricing and cost efficiencies. - Overall, margin expansion is expected from improved product mix, mix premiumization, operating leverage, and cost management.

The document does not provide any specific information about the current or expected order book or pending orders for Parag Milk Foods Limited. During the Q&A and management commentary on page 22 and other pages, the discussion primarily focuses on sales growth, product categories (paneer, curd, whey protein), working capital, cash flow, debt, margins, and distribution networks. There is no mention or disclosure of order book status or pending orders in the provided pages of the transcript.